Lucid Diagnostics Inc Insider Dennis Matheis Acquires 100,000 Shares, Boosts Stake to 665,443 Shares.

Dennis Matheis, Director at Lucid Diagnostics Inc (LUCD), acquired 100,000 shares on August 20, 2025, bringing his total to 665,443 shares. Over the past year, Matheis has acquired 800,000 shares without selling any. The company focuses on esophageal precancer and cancer detection. Insider buying trend indicates positive sentiment among insiders.

Lucid Diagnostics Inc. (LUCD) experienced a significant insider buying event on August 20, 2025, as Director Dennis Matheis acquired 100,000 shares of the company's Common Stock. This transaction, filed under SEC Form 4, occurred at a weighted average price of $1.0184 per share, totaling $101,840 [1].

Matheis' acquisition brings his total shareholding to 665,443 shares. Over the past year, he has acquired 800,000 shares without selling any, indicating a strong bullish sentiment among insiders. This trend is notable as it suggests that key executives believe in the company's potential for growth, particularly in the realm of esophageal precancer and cancer detection [2].

The insider buying trend can be seen as a positive indicator for investors, as it often reflects confidence in the company's future prospects. However, it is essential to consider other factors, such as the company's financial health and market conditions, before making investment decisions.

References:
[1] https://www.sec.gov/Archives/edgar/data/1799011/000106299325014853/xslF345X05/form4.xml
[2] https://www.tradingview.com/news/tradingview:69a5ce3d02401:0-lucid-diagnostics-director-dennis-matheis-acquires-100-000-shares/